Dr Eleni Efstathiou chairs a discussion with Prof Thomas Steuber, Prof Peter Goebell and Prof Joaquim Bellmunt on the recent data presented at the 2019 GU Debates in Budapest, with a specific focus on patients with prostate and urothelial cancers.
In this video, the group acknowledge the sudden shift in bladder cancer research - which has resulted from genomic advances; including the use of The Cancer Genome Atlas Program (TCGA).
A more personalised treatment approach is anticipated in first-line metastatic urothelial carcinoma, along with checkpoint inhibition and targeted therapies; with potential applicability to the second-line setting.
The group also discuss novel data showing prolonged survival in the metastatic setting with immunotherapeutic agents; along with five phase III trials - in which the results are expected to be practice-changing.
They also conclude the discussion by highlighting the importance of patient communication in the clinic.
Watch part 1 of this video which covers the changing treatment paradigms for hormone-naïve and castration-resistant prostate cancer here.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).